FibroGen (NASDAQ:FGEN - Get Free Report) is expected to post its quarterly earnings results before the market opens on Monday, February 24th. Analysts expect FibroGen to post earnings of ($0.14) per share and revenue of $24.91 million for the quarter.
FibroGen Price Performance
FGEN traded down $0.01 during trading on Wednesday, hitting $0.58. 604,446 shares of the stock traded hands, compared to its average volume of 1,062,670. The firm has a market capitalization of $57.94 million, a P/E ratio of -0.47 and a beta of 0.75. The firm has a 50-day moving average of $0.50 and a 200 day moving average of $0.42. FibroGen has a 12-month low of $0.18 and a 12-month high of $2.80.
Analyst Upgrades and Downgrades
Several equities research analysts have weighed in on the stock. HC Wainwright raised shares of FibroGen to a "strong-buy" rating in a research report on Tuesday, December 17th. William Blair reaffirmed a "market perform" rating on shares of FibroGen in a research report on Wednesday, November 13th. Finally, StockNews.com assumed coverage on shares of FibroGen in a research report on Thursday, February 13th. They issued a "hold" rating for the company.
View Our Latest Report on FGEN
FibroGen Company Profile
(
Get Free Report)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.
Featured Articles
Before you consider FibroGen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and FibroGen wasn't on the list.
While FibroGen currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
